The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation, which leads to the reduced clearance of low dens...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur Heart J
Asıl Yazarlar: Landlinger, Christine, Pouwer, Marianne G., Juno, Claudia, van der Hoorn, José W.A., Pieterman, Elsbet J., Jukema, J. Wouter, Staffler, Guenther, Princen, Hans M.G., Galabova, Gergana
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Basic Science
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5837708/
https://ncbi.nlm.nih.gov/pubmed/28637178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehx260
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller